Dexcom (Nasdaq:DXCM) is one of the leaders in the diabetes technology space with its continuous glucose monitoring (CGM) technology. The company’s current-generation Dexcom G6 CGM remains one of the biggest players in the CGM space. Meanwhile, its next-generation Dexcom G7 CGM has already launched in a number of countries overseas. The wearable device — which […]
Patient Monitoring
Dexcom launches NIL program for college athletes with diabetes
Dexcom (Nasdaq:DXCM) announced today that it launched Dexcom U, an NIL (name, image, likeness) program for college athletes. The San Diego-based company aims for the program to celebrate college athletes with diabetes. The company labeled it the first-ever NIL program designed to do so. Dexcom also hopes it inspires those with diabetes to pursue athletic […]
Medtronic launches diabetes insights program for MiniMed users
Medtronic (NYSE:MDT) announced today that it introduced a new diabetes management program for users of the MiniMed 770G insulin pump. The medtech giant calls the new program My Insights. It designed it exclusively for individuals using the MiniMed 770G hybrid closed-loop insulin delivery system. Using an individual’s data, My Insight provides personalized tips, trends and […]
GlucoTrack hires former Dexcom scientist as VP of sensor technology
GlucoTrack (Nasdaq:GCTK) announced today that it appointed Mark Tapsak as its vice president of sensor technology. Tapsak, a veteran of more than 25 years in the diabetes industry, joins the company, effective immediately. His experience includes time spent as a medical device research scientist. He focused on polymer synthesis, polymer characterization, medical device design and […]
GlucoTrack to begin R&D for new long-term CGM
GlucoTrack (Nasdaq:GCTK) announced that it plans to expand its product pipeline with a R&D program for a long-term continuous glucose monitor (CGM). Rutherford, New Jersey-based GlucoTrack said it recently required related IP. It now intends to develop a long-term, implantable glucose management platform for the type 1 diabetes market. Initial data gives the company confidence […]
Ascensia completes Senseonics Eversense E3 European launch
Ascensia Diabetes Care announced that it successfully completed its initial European launch for the Senseonics (NYSE:SENS) Eversense E3. Eversense E3 represents Senseonics’ next-generation continuous glucose monitor (CGM) system. Eversense E3 can be used for up to six months (180 days). This doubles the wear time of its previous-generation CGM. Ascensia said in a news release […]
Analysts: Abbott, Dexcom to benefit from proposed CMS decision on CGMs
Analysts see a new proposed local coverage determination (LCD) from CMS as a potential boost for Dexcom (Nasdaq:DXCM) and Abbott (NYSE:ABT). The Centers for Medicare and Medicaid Services (CMS) yesterday published the LCD modifying coverage criteria for continuous glucose monitors (CGMs). The modification includes people with diabetes who receive insulin treatment or have a history […]
Senseonics offers equity grants under inducement plan
Senseonics (NYSE:SENS) announced today that it granted six new non-executive employees stock options under an inducement plan. Germantown, Maryland-based Senseonics granted the employees non-qualified stock options. The options allow them to purchase an aggregate of 78,000 shares of the company’s common stock. It represents an inducement for such employees to join the company, according to a […]
Study shows reduced HbA1c with Abbott FreeStyle Libre 2 CGM
Abbott (NYSE:ABT) announced today that a new study supports the use of its FreeStyle Libre 2 continuous glucose monitor (CGM). The study, published in The New England Journal of Medicine, evaluated adults with type 1 diabetes and suboptimal glycemic control. It demonstrated significant reductions in glycated hemoglobin (HbA1c) compared to self-monitoring of blood glucose. Subjects […]
Published data backs digital therapeutic for diabetes from Better Therapeutics
Better Therapeutics (Nasdaq:BTTX) announced today that newly published data supports its digital therapeutic for type 2 diabetes. San Francisco-based Better Therapeutics develops the BT-001 prescription digital therapeutic (PDT). It potentially represents the first-in-class PDT using cognitive behavioral therapy (CBT) to treat type 2 diabetes. In July, the company completed the pivotal trial for its BT-001 digital therapeutic […]